|
EC: Scrutiny Leads to Decline in ‘Problematic’ Patent Deals
The number of patent settlements between brand- and generic-drug makers considered by the European Commission (EC) to be “potentially problematic” has fallen since the commission increased its scrutiny of the deals, a new report says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives